DVAX
Dynavax Technologies Corporation · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +3.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 6.79M | -12.9% | $88.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.07M | +2.4% | $39.77M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 2.71M | +14.9% | $35.09M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 2.49M | +29.6% | $32.25M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 1.32M | +51.9% | $17.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Marshall Wace ✦ | 875.86K | New | $11.36M | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | Fisher Asset Management ✦ | 622.05K | -52.1% | $8.07M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 602.98K | +12220.9% | $7.82M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 226.51K | +24.3% | $2.94M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 96.56K | +10.4% | $1.25M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 11 | Wellington Management ✦ | 56.72K | -5.1% | $735,607 | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 12 | Gotham Asset Management ✦ | 53.70K | +281.8% | $696,463 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $11.36M | 0.0% |
Exited
| Norges Bank | $7.76M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 6 shares, $93 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.